Company intelligence / Profile preview

Recursive Health

Salt Lake City, Utah, United Statesrecursive.health ↗

Ownership: Private
Employees: ~640
Development stage: Commercial

Overview

Recursion has advanced several programs into clinical trials using its AI-driven drug discovery platform. Its lead asset REC‑3565 entered a Phase I trial for relapsed/refractory B-cell lymphomas. Other assets target rare diseases and oncology indications; early data readouts are expected soon.

Therapeutic areas: OncologyRare DiseasesNeurologyInfectious Diseases
Modalities: Small moleculeGene therapyBiologic (potentially; platform agnostic but primarily small molecules and gene therapies)mRNA-based drugs (possible based on AI/automation focus; not explicitly confirmed)
Industry: Biotech

Partnerships

NVIDIA (AI/cloud computing partnership)pharmaceutical companies for co-development/licensing deals (undisclosed partners)academic collaborations

Beyond the preview

Go deeper on Recursive Health.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Recursive Health.

Explore the full profile